Hims Weight Loss Review: How the GLP-1 Program Works

Yes, Hims weight loss is a real, licensed telehealth program run by a publicly traded company, and as of October 2026 it is built mainly around FDA-approved GLP-1 medications from the two companies that make them. It also has a documented regulatory record from 2025 and 2026, including an FDA warning letter and a pending Federal Trade Commission lawsuit over billing and privacy, that anyone asking "is Hims weight loss legit" deserves to see in one place.

• Hims & Hers Health, Inc. trades on the New York Stock Exchange under the ticker HIMS. It sells weight-loss care to men through hims.com and to women through forhers.com.
• When we checked hims.com in October 2026, its weight-loss page listed Wegovy (pill and pen), Zepbound (vial and KwikPen), the Foundayo pill, Ozempic and Mounjaro. Hims notes that Ozempic and Mounjaro are FDA-approved for type 2 diabetes, not weight loss.
• In March 2026, Hims said it would stop advertising compounded GLP-1s and would offer compounded semaglutide only on a limited scale, when a provider decides it is clinically necessary. Compounded medications are not FDA-approved.
• A Weight Loss Membership is required, is billed separately from medication, and does not include or guarantee a prescription, according to Hims's own site.
• On July 29, 2026, the FTC, joined by Utah and California, sued Hims & Hers over billing, cancellation and health-data sharing. Those are allegations; the case is pending and Hims denies them.

Disclosure: Rx.com runs its own GLP-1 weight-loss program, so Hims is a competitor. We have tried to describe Hims fairly, using its own published materials, government records and major news coverage, and we link every source at the bottom of the page.

What Hims Weight Loss Is

Hims weight loss is the GLP-1 program run by Hims & Hers Health, Inc., a direct-to-consumer telehealth company that also treats hair loss, sexual health, skin care and mental health. Men sign up through hims.com and women through forhers.com. Hims says it has been providing care online since 2017, and its BBB profile lists Andrew Dudum as chief executive. The company's filings describe operations in the United States, the United Kingdom, Canada and the European Union, and in 2026 it announced expansion into Australia.

The U.S. weight-loss program is branded "Weight Loss by Hims." Hims describes it as a program that combines nutrition support, technology tools and medication that a provider decides is medically appropriate. Its weight-loss medical team is led by Dr. Craig Primack, whom the company identifies as its senior vice president of weight management.

The most important thing to understand about Hims in late 2026 is that the program looks very different from the one most older reviews describe. Until early 2026, much of the coverage of Hims weight loss focused on its compounded medication (compounded drugs are not FDA-approved). In March 2026 the company announced what it called a "strategic shift" for its U.S. weight-loss business, and the menu you see today is built around FDA-approved products. If a review you are reading does not mention that shift, it is out of date.

How the Hims GLP-1 Program Works

Based on what Hims publishes on its weight-loss page and FAQ as of October 2026, the process runs in roughly these steps:

1. Online intake. You answer questions about your health history, current medications and goals. Hims also lets you say up front whether you want a pill, an injection or a provider recommendation.
2. Provider review. A licensed provider reviews your intake and decides whether a prescription is appropriate. Hims's company filings say U.S. consultations are delivered through "Affiliated Medical Groups," which are professional corporations owned by licensed physicians.
3. Membership. To receive medication you need an active Weight Loss Membership. Hims states that medication is not available without one, that the membership is billed separately, and that it does not include or guarantee a prescription.
4. Pharmacy and shipping. If you are prescribed a medication, it is filled by a pharmacy and shipped to you. Hims's filings say it uses both third-party partner pharmacies and pharmacies it owns. The company's own description on Trustpilot says prescribed treatment ships at no extra cost.
5. Ongoing care. The membership includes 24/7 messaging with licensed providers, dosage adjustments, in-app weight tracking, support for common side effects, a private peer community and an optional smart scale that ships separately.

A few details are worth knowing before you start:

• Switching from another provider. If you already take a GLP-1, Hims says you complete an intake so its providers can review your current treatment, and that in many cases care can continue without starting over.
• Side effect support. Hims notes that a provider may prescribe ondansetron (Zofran) off-label for GLP-1 nausea, at the provider's discretion.
• AI in the app. Hims says AI-generated responses in its app are not medical advice and that a licensed provider is always available. It describes AI support as a feature rolling out over time.
• Partner perks. Active members get discounts from partners Hims lists as HelloFresh, MyFitnessPal and Ladder.
• Availability. Hims states the program is not available in all 50 states. Check your state during sign-up.

What Hims Prescribes for Weight Loss

As of October 2026, Hims's weight-loss page lists only brand-name, FDA-approved products. This is the list we saw when we checked the page this month. Availability can change, so treat the company's site as the final word.

The Novo Nordisk products arrived through a formal collaboration. Hims announced the agreement on March 9, 2026, and said on March 26, 2026 that Wegovy injections, Wegovy pills and Ozempic were available to eligible customers. The Eli Lilly products are a different arrangement: Hims's site states that Hims is not affiliated with or endorsed by Eli Lilly. Hims notes that Ozempic and Mounjaro are approved for type 2 diabetes and are available only to patients a provider judges clinically eligible.

What changed in March 2026

Compounded semaglutide, which is not FDA-approved, was a central part of Hims's U.S. weight-loss offering in 2025, and it was at the center of the company's regulatory and legal disputes. In its March 9, 2026 announcement, Hims said it would no longer advertise compounded GLP-1 offerings on its platform or in its marketing. It said compounded semaglutide would remain available "on a limited scale," and only when a provider determines that a compounded product is clinically necessary, which it expects to apply to a limited group of customers whose needs approved options cannot meet.

Compounded medications are not FDA-approved, which means the FDA does not review them for safety, effectiveness or quality before they reach patients. When we checked the Hims weight-loss page in October 2026, it did not list a compounded product. If a provider ever suggests one, ask why an approved option does not fit your situation and which pharmacy will make it.

Is Hims Weight Loss Legit?

Hims is a legitimate company: it is publicly traded, files reports with the SEC, works with physician-owned medical groups, and now offers FDA-approved medications under a formal agreement with Novo Nordisk. It is also accredited by the Better Business Bureau. At the same time, few telehealth companies have had more regulatory attention in the past two years. Here is the documented record, in order.

2025: a short partnership with Novo Nordisk

In April 2025, Novo Nordisk announced a collaboration that let Hims customers access its brand-name weight-loss medication. Novo ended that collaboration in June 2025.

Novo's stated reason was Hims's continued sale of compounded semaglutide, which is not FDA-approved. Novo's executive vice president of U.S. operations, Dave Moore, was quoted saying the company would "continue to take action" against what it called illegal sham compounding. Hims kept selling compounded semaglutide by relying on a legal exception for prescriptions customized to an individual patient, according to Associated Press reporting.

September 2025: FDA warning letters

On September 9, 2025, the FDA sent Hims & Hers two warning letters, one for hims.com and one for forhers.com. The letters cited website claims that the company's compounded semaglutide had the "same active ingredient" as FDA-approved brand-name drugs, and that it contained "clinically proven ingredients." The FDA said these claims implied the compounded products were the same as approved drugs, which they are not (compounded drugs are not FDA-approved), and that this made the products misbranded under federal law. The FDA asked for a written response within 15 working days. A warning letter is a formal notice of the agency's concerns, not a court ruling.

February 2026: a pill launch, a federal referral and a lawsuit

In early February 2026, Hims announced a compounded semaglutide pill (compounded drugs are not FDA-approved). On February 6, the FDA said it would take steps to restrict compounded GLP-1s from being mass-marketed as similar to approved drugs, naming Hims, and HHS's general counsel said HHS had referred Hims to the Department of Justice for possible violations of the Federal Food, Drug, and Cosmetic Act. On February 7, Hims said it had "decided to stop offering access to this treatment." On February 9, Novo Nordisk sued Hims for patent infringement; Hims called the suit an attack on consumer choice. We found no public report of how the DOJ referral was resolved as of October 2026.

March 2026: settlement and strategic shift

On March 9, 2026, Novo Nordisk said it was dismissing its lawsuit without prejudice, meaning it kept the right to refile, and the two companies announced a collaboration. Hims said at the same time that it would stop advertising compounded GLP-1s, which are not FDA-approved. Its second-quarter 2026 report describes this as a strategic shift that aligns its U.S. weight-loss business with its approach to branded medications elsewhere.

July 2026: FTC lawsuit over billing and privacy

On July 29, 2026, the FTC, joined by Utah and by California through Los Angeles County Counsel, filed a lawsuit against Hims & Hers in federal court in Northern California. According to the FTC, the complaint alleges that Hims:

• did not clearly disclose that it charges consumers almost immediately after they submit an intake form, and that many consumers were charged for and subscribed to a treatment without first reviewing or approving it;
• did not clearly disclose when monthly refills occur;
• made cancellation hard, including, after online cancellation was added in 2023, placing the cancel option behind an "add/remove items from order" path; and
• shared consumers' health information with advertising platforms, including Meta and Snap, despite privacy promises.

These are allegations. The FTC's own release says the court will decide the case, and the FTC case page listed it as pending in October 2026. Hims responded the same day that the suit ignores evidence it provided during a nearly three-year investigation, that customers can choose how their data is used under its privacy policy, and that it will defend itself. The FTC's press release does not single out the weight-loss program; it describes Hims's telehealth business generally.

What the BBB shows

Hims & Hers Inc. is BBB-accredited. In October 2026, its BBB profile displayed a notice about the pending FTC case, and its recent customer reviews there focused on cancellations and renewal charges. The refund policy shown on the BBB profile says sales are final and not eligible for a refund, and that Hims will try to replace a package that arrives damaged or wrong.

What Hims GLP-1 Reviews Say

We read recent public reviews on Trustpilot and the BBB in October 2026. These are self-selected comments, not a survey, and Trustpilot notes that Hims invites customers to leave reviews. Reviews on Hims's profile also cover its hair-loss and sexual-health products, so we focused on weight-loss comments. Here are the recurring themes.

What people like

• Easy start. Many reviewers say the online questionnaire and video consultation were simple and fast.
• Responsive providers. Several weight-loss reviewers describe messages being answered promptly and a provider adjusting their prescription when they reported a problem.
• Results for some. Some members report steady weight loss and reduced appetite. Others report little change, which is consistent with how individual responses to these medications vary.
• Replies to complaints. Trustpilot shows Hims replying to nearly all negative reviews.

What people complain about

• Unexpected charges. The most common complaint is being charged a membership or subscription fee earlier, or in a different way, than the reviewer expected, often while still finding out whether they qualified.
• Cancellation. Reviewers on both sites describe trouble cancelling, or being billed again after they believed they had cancelled.
• Refill and shipping gaps. Some describe delays that left them without medication for days or weeks between refills.
• Total cost. Trustpilot's AI summary of recent reviews flags overall membership and medication cost as a source of frustration.
• Support quality. Some say support is hard to reach or relies on automated chat.

What Affects the Cost of Hims Weight Loss

We do not quote prices on this page, because they change often and Hims publishes its own current pricing on hims.com. What we can tell you is how the cost is built, so you can compare it fairly:

• Two separate charges. You pay for a Weight Loss Membership and, if prescribed, for the medication. Hims says the membership is billed separately and is not included in the medication price.
• An introductory first month. Hims's site shows a lower first-month membership charge that then auto-renews monthly at the regular rate.
• Which medication and dose. Medication prices on the Hims page differ by product, and the brand-name makers' own pricing structures can vary by dose.
• Insurance. Hims says insurance is not required. Its FAQ does not describe billing insurance for weight-loss medication.
• FSA and HSA. Hims says the medication fee is FSA/HSA eligible but the membership fee is not, and that you may need to pay by card and submit a receipt for reimbursement.

To compare honestly, add the membership and the medication together, for the dose you expect to be on after a few months, not just the first month.

Pros and Cons of Hims Weight Loss

Pros

• Wide choice of FDA-approved GLP-1s, including pills and injections, from both major manufacturers
• Formal collaboration with Novo Nordisk since March 2026
• 24/7 messaging with licensed providers and in-app tracking
• Publicly traded company that discloses its business in SEC filings
• No insurance needed, and medication fees are FSA/HSA eligible
• Help switching from another GLP-1 provider without starting over

Cons

• Membership required on top of medication, and it does not guarantee a prescription
• Pending FTC lawsuit alleging billing, cancellation and data-sharing problems
• FDA warning letters in 2025 and a DOJ referral in 2026 over past marketing of compounded semaglutide, which is not FDA-approved
• Recurring public complaints about unexpected charges and cancellation
• Refund policy shown on its BBB profile says sales are final
• Not available in every state

Alternatives to Hims for GLP-1 Weight Loss

Rx.com's GLP-1 program

Rx.com runs its own online weight-loss program with an online visit with a licensed U.S. provider. There is one price at every dose, no insurance is needed, medication ships to your door, and you are not charged for medication if you are not approved. Rx.com is LegitScript certified. See if Rx.com's GLP-1 program is right for you.

Your own doctor and your insurance

If you have a primary care doctor or an obesity medicine specialist, ask whether an FDA-approved GLP-1 is appropriate and whether your plan covers it. Coverage for weight loss varies widely by plan, and prior authorization is common. If your plan covers the medication, this can be the lowest-cost route.

The manufacturers' self-pay pharmacies

Both makers of the brand-name GLP-1s sell directly to self-pay patients with a valid prescription: Eli Lilly through LillyDirect and Novo Nordisk through NovoCare Pharmacy. Some telehealth companies route prescriptions to these channels. If you already have a prescriber, going direct can remove a membership layer.

Other telehealth GLP-1 programs

Ro and Noom also offer GLP-1 programs with different structures. Ro emphasizes help with insurance coverage, and Noom pairs medication with its behavior-change app. See our Ro weight loss review and Noom GLP-1 review.

How Rx.com Differs

Rx.com's program is built to be simple to understand before you pay anything for medication. You start with an online visit with a licensed U.S. provider. If the provider approves treatment, your medication ships to your door. If you are not approved, you are not charged for medication. You do not need insurance.

Rx.com prescribes compounded semaglutide and compounded tirzepatide, and the price is the same at every dose, so moving up a dose does not raise your bill. Compounded medications are not FDA-approved, and the FDA does not review them for safety, effectiveness or quality. Rx.com is LegitScript certified.

Which program fits depends on what you value. If a specific brand-name medication matters most to you, Hims and the manufacturers' own pharmacies offer them. If predictable pricing and not paying for medication unless you are approved matter more, Rx.com is worth a look.